40
Participants
Start Date
March 11, 2022
Primary Completion Date
August 5, 2024
Study Completion Date
August 5, 2024
Empagliflozin (Jardiance®;
Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
Placebo Control Intervention
Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
University Hospital Berne and Center of Bariatric Surgery Berne, Bern
University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism, Basel
Cantonal Hospital Olten, Endocrine Outpatient Clinic, Olten
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
University Hospital, Basel, Switzerland
OTHER